Adverse Event Scale in Patients With Epilepsy (aEscape) - A European Survey for Physicians With Epilepsy Patients
A Multicenter, Non-interventional Surveillance Study to Evaluate the Adverse Effects of Antiepileptic Drug Treatment in Patients With Epilepsy
1 other identifier
observational
1,000
7 countries
53
Brief Summary
The purpose of the survey is to explore through a structured interview and patient examination the rate and distribution of neurological and systemic adverse effects related to antiepileptic treatment. Adverse effects and considerations to modify the therapy will be assessed in pediatric and adult patients with controlled as well as uncontrolled epilepsy with different seizure types
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2007
Shorter than P25 for all trials
53 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 1, 2006
CompletedFirst Posted
Study publicly available on registry
November 2, 2006
CompletedStudy Start
First participant enrolled
April 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2007
CompletedJuly 19, 2012
July 1, 2012
4 months
November 1, 2006
July 18, 2012
Conditions
Keywords
Eligibility Criteria
Patients with confirmed diagnosis of epilepsy requiring anti-epileptic treatment and which are already receiving daily anti-epileptic treatment
You may qualify if:
- Male and female patients from the age of 4 years
- Confirmed diagnosis of epilepsy requiring AED treatment
- Patients already receiving daily AED treatment as a monotherapy or a polytherapy with maximum 2 AEDs within the terms of marketing authorization with the following medications: Carbamazepine, Clobazam, Clonazepam, Gabapentin, Lamotrigine, Levetiracetam, Oxcarbazepine, Phenobarbital, Phenytoin, Pregabalin, Tiagabine, Topiramate, Valproate, Zonisamide
- Treatment must be stable for at least 3 months prior to assessment
- Absence of other severe and/or uncontrolled symptomatic chronic illness
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- UCB Pharmalead
- International Bureau for Epilepsycollaborator
Study Sites (53)
Unknown Facility
Vienna, Austria
Unknown Facility
Blansko, Czechia
Unknown Facility
České Budějovice, Czechia
Unknown Facility
Hradec Králové, Czechia
Unknown Facility
Karlovy Vary, Czechia
Unknown Facility
Kopřivnice, Czechia
Unknown Facility
Kroměříž, Czechia
Unknown Facility
Liberec, Czechia
Unknown Facility
Litomyšl, Czechia
Unknown Facility
Náchod, Czechia
Unknown Facility
Nové Město na Moravě, Czechia
Unknown Facility
Prague, Czechia
Unknown Facility
Teplice, Czechia
Unknown Facility
Třebíč, Czechia
Unknown Facility
Ústí nad Labem, Czechia
Unknown Facility
Zlín, Czechia
Unknown Facility
Aschaffenburg, Germany
Unknown Facility
Berlin, Germany
Unknown Facility
Bielefeld, Germany
Unknown Facility
Bochum, Germany
Unknown Facility
Cologne, Germany
Unknown Facility
Düsseldorf, Germany
Unknown Facility
Ellwangen, Germany
Unknown Facility
Göttingen, Germany
Unknown Facility
Hirschaid, Germany
Unknown Facility
Jena, Germany
Unknown Facility
Königsbrück, Germany
Unknown Facility
Krefeld, Germany
Unknown Facility
Leipzig, Germany
Unknown Facility
München, Germany
Unknown Facility
Neuberg, Germany
Unknown Facility
Oelde, Germany
Unknown Facility
Albano Laziale (Roma), Italy
Unknown Facility
Napoli, Italy
Unknown Facility
Bialystok, Poland
Unknown Facility
Elblag, Poland
Unknown Facility
Gdansk, Poland
Unknown Facility
Katowice, Poland
Unknown Facility
Kielce, Poland
Unknown Facility
Krakow, Poland
Unknown Facility
Lublin, Poland
Unknown Facility
Poznan, Poland
Unknown Facility
Warsaw, Poland
Unknown Facility
Wroclaw, Poland
Unknown Facility
Botoșani, Romania
Unknown Facility
Brasov, Romania
Unknown Facility
Bucharest, Romania
Unknown Facility
Craiova, Romania
Unknown Facility
Galati, Romania
Unknown Facility
Iași, Romania
Unknown Facility
Lasi, Romania
Unknown Facility
Timișoara, Romania
Unknown Facility
Sant Boi de Llobregat, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Sonja Buyle, M.D.
UCB Pharma
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
November 1, 2006
First Posted
November 2, 2006
Study Start
April 1, 2007
Primary Completion
August 1, 2007
Study Completion
August 1, 2007
Last Updated
July 19, 2012
Record last verified: 2012-07